Therapeutic Asset Ratings

122 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Natalizumab Sickle Cell Disease	Washington University School of Medicine	P1	CC (40)
Omeprazole Sickle Cell Disease	Pfizer	P1	CC (40)
REPAGLINIDE Sickle Cell Disease	Pfizer	P1	CC (40)
Rosuvastatin Sickle Cell Disease	Pfizer	P1	CC (40)
Wellbutrin Sickle Cell Disease	Pfizer	P1	CC (40)
Arestin Sickle Cell Disease	University of Cincinnati	P1	C (37)
Autologous Bone Marrow Derived Cd34+ Hspcs Electroporated With Bcl11A Enhancer Targeting Cas9 Ribonucleoprotein Sickle Cell Disease	Daniel Bauer	P1	C (37)
Disc-3405 Sickle Cell Disease	Disc Medicine, Inc	P1	C (37)
Fostamatinib Sickle Cell Disease	National Heart, Lung, and Blood Institute (NHLBI)	P1	C (37)
Gene-Modified Cd34+ Cells Sickle Cell Disease	St. Jude Children's Research Hospital	P1	C (37)
LLP2A-CB-TE1A1P CU-64 Sickle Cell Disease	Enrico Novelli	P1	C (37)
Multiple Vitamins Injection Sickle Cell Disease	EpiDestiny, Inc.	P1	C (37)
otq923 Sickle Cell Disease	Novartis Pharmaceuticals	P1	C (37)
Panobinostat Sickle Cell Disease	Abdullah Kutlar	P1	C (37)
Mgta-145 Sickle Cell Disease	Ensoma	P2	C (36)
cs-206 Sickle Cell Disease	Children's Hospital of Fudan University	Early P1	C (34)
T-CELL SURFACE ANTIGEN T4/LEU-3 Sickle Cell Disease	City of Hope Medical Center	P1	D (28)
Brl-101 Sickle Cell Disease	Bioray Laboratories	N/A	D (28)
Carbon Dioxide Sickle Cell Disease	Washington University School of Medicine	N/A	D (28)
IMMUNOGLOBULIN G4, ANTI-(HUMAN LYSYL OXIDASE HOMOLOG 2) (HUMAN-MUS MUSCULUS MONOCLONAL GS-6624 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL GS-6624 .KAPPA.-CHAIN, DIMER Sickle Cell Disease	New York University	N/A	D (28)
kl003 cell Sickle Cell Disease	Institute of Hematology & Blood Diseases Hospital, China	N/A	D (28)
Omnipaque Sickle Cell Disease	University Hospital, Tours	N/A	D (28)

Showing 101 to 122 of 122 assets

PreviousPage 5 of 5Next